Band-Aid, Tylenol Parent Kenvue Reports Healthy Full-Year Guidance

Group 1 - Kenvue affirmed its full-year revenue growth projection, with the midpoint exceeding analysts' expectations [1][2] - The company reported second-quarter revenue of $4 billion, slightly beating consensus estimates [3] - Kenvue shares surged 13% in intraday trading following the positive guidance affirmation [1] Group 2 - Kenvue expects 2024 net sales growth between 1% and 3%, with the midpoint at 1.4%, which is above analysts' expectations [2] - The CEO stated that the transformation efforts are yielding results and the company is on track to meet its financial targets for 2024 [2] - In Q2, Kenvue posted earnings per share (EPS) of 3 cents, missing the expected 24 cents, but adjusted EPS of 32 cents exceeded estimates [3]